100
Participants
Start Date
August 15, 2018
Primary Completion Date
May 26, 2021
Study Completion Date
May 11, 2023
Paclitaxel
175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.
Bevacizumab
15 mg/kg IV infusion on Day 1 of each 21-day cycle.
Carboplatin
Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
Placebo
Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing
the First Hospital of Jilin University, Changchun
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing
Nantong Tumor Hospital, Nantong
Tianjin Medical University General Hospital, Tianjin
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou
Fujian Cancer Hospital, Fuzhou
Xiangya Hospital Central South University, Changsha
Henan Cancer Hospital, Zhengzhou
Sun Yet-sen University Cancer Center, Guangzhou
Guangxi Cancer Hospital of Guangxi Medical University, Nanning
West China Second University Hospital, Chengdu
First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an
Hoffmann-La Roche
INDUSTRY